National shared care protocol:

Methylphenidate in adult services

A logo with a blue and white logo

Description automatically generated17 July 2024, Version 1.1

**SWL Local Adaptation**

**2023**

Please follow link to local amendment regarding[Locally agreed off-label use](#_Locally_agreed_off-label)

Please follow link to local addition to [appendix 1](#_Appendix_1:_Shared) and [appendix 2](#_Appendix_2:_Shared). This has been added to clearly define who will be responsible for completing the annual review specified in [Section 8](#_Baseline_investigations,_initial) under ‘Ongoing Monitoring’ and [Section 9](#_Ongoing_monitoring_requirements). Work is being done to allow for the annual review to be conducted in primary care **only** where local arrangements allow for this. The specialist is responsible for ensuring local arrangements are in place prior to suggesting that the primary care prescriber could undertake the annual review.

**Version Control History**

Date: July 2024

Version: 1.1

Type of change: Minor

Summary of changes: NICE endorsement of off-label indication (section 2 & 6). Addition of newly available branded generics (section 6).

Approved by: Integrated medicines committee (IMOC)

Approval date:17th July 2024

Review Date: January 2025, , as per NHS England. Extended to February 26, agreed by Integrated Medicines Optimisation Committee January 25.

**The content of this shared care protocol was correct as of January 2022. As well these protocols, please ensure that**[**summaries of product characteristics**](https://www.medicines.org.uk/emc/)**(SPCs),**[**British national formulary**](https://bnf.nice.org.uk/?)**(BNF) or the**[**Medicines and Healthcare products Regulatory Agency**](https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency)**(MHRA) or**[**NICE**](https://www.nice.org.uk/)**websites are reviewed for up-to-date information on any medicine.**

|  |
| --- |
| Specialist responsibilities  * Assess the patient and provide diagnosis. Ensure the diagnosis is within scope of this shared care protocol (section 2) and communicated to primary care. * Use a shared decision making approach; discuss the benefits and risks of the treatment with the patient and/or their carer and provide the appropriate counselling (see section 11), to enable the patient to reach an informed decision. Obtain and document consent. Provide an appropriate patient information leaflet. * Ensure the patient and/or their carer understands that treatment may be stopped if they do not attend for monitoring and treatment review * Assess for contraindications and cautions (see section 4) and interactions (see section 7). * Conduct required baseline investigations and initial monitoring (see section 8). * Initiate and optimise treatment as outlined in section 5. Prescribe the maintenance treatment for at least 4 weeks and until optimised. * Prescribe in line with controlled drug prescription requirements (section 6). * Once treatment is optimised, complete the shared care documentation and send to patient’s GP practice detailing the diagnosis, brand to be prescribed, current and ongoing dose, any relevant test results and when the next monitoring is required. Include contact information (section 13). * Prescribe sufficient medication to enable transfer to primary care, including where there are unforeseen delays to transfer of care. * Conduct the required monitoring in section 8 and communicate the results to primary care. This monitoring, and other responsibilities below, may be carried out by a healthcare professional in primary or secondary care with expertise and training in ADHD, depending on local arrangements. * Determine the duration of treatment and frequency of review. After each review, advise primary care whether treatment should be continued, confirm the ongoing dose, and whether the ongoing monitoring outlined in section 9 remains appropriate. Trial discontinuations should be managed by the specialist. * Reassume prescribing responsibilities if a woman becomes or wishes to become pregnant. * Provide advice to primary care on the management of adverse effects if required.  Primary care responsibilities  * Respond to the request from the specialist for shared care in writing. It is asked that this be undertaken within 14 days of the request being made, where possible. * If shared care is accepted, prescribe ongoing treatment as detailed in the specialist’s request and as per section 5, taking into account any potential drug interactions in section 7. * Prescribe in line with controlled drug prescription requirements (section 6). * Adjust the dose of methylphenidate prescribed as advised by the specialist. * Conduct the required monitoring as outlined in section 9. Communicate any abnormal results to the specialist. * Assess for possible interactions with methylphenidate when starting new medicines (see section 7). * Manage any adverse effects as detailed in section 10 and discuss with specialist team when required. * Stop methylphenidate and make an urgent referral for appropriate care if cerebral ischaemia, new or worsening seizures, or serotonin syndrome are suspected. * Refer the management back to the specialist if the patient becomes or plans to become pregnant. * Stop treatment as advised by the specialist. Trial discontinuations should be managed by the specialist.  Patient and/or carer responsibilities  * Take methylphenidate as prescribed, and avoid abrupt withdrawal unless advised by their prescriber. * Attend regularly for monitoring and review appointments with primary care and specialist, and keep contact details up to date with both prescribers. Be aware that medicines may be stopped if they do not attend. * Report adverse effects to their primary care prescriber. Seek immediate medical attention if they develop any symptoms as detailed in section 11. * Report the use of any over the counter medications (OTC) to their primary care prescriber and be aware they should discuss the use of methylphenidate with their pharmacist before purchasing any OTC medicines. * Not to drive or operate heavy machinery if methylphenidate affects their ability to do so safely, and inform the DVLA if their ability to drive safely is affected (see section 11). * Avoid alcohol during treatment, as it may make some side effects worse. Avoid recreational drugs. * Methylphenidate is a schedule 2 controlled drug. Patients may be required to prove their identity when collecting prescriptions, and should store methylphenidate safely and securely. It must not be shared with anyone else. * Patients of childbearing potential should take a pregnancy test if they think they could be pregnant, and inform the specialist or GP immediately if they become pregnant or wish to become pregnant. |
| Background [Back to top](#Responsibilities) |
| Methylphenidate is a central nervous system stimulant licensed as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD). It may be offered as a first line pharmacological treatment option for adults with ADHD who have been appropriately diagnosed (see NICE Guidance NG87 Attention deficit hyperactivity disorder: diagnosis and management). NICE recommends that people with ADHD have a comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or educational needs.  Methylphenidate is available as immediate-release tablets, and modified-release tablets and capsules. The modified-release preparations contain both immediate-release and prolonged-release methylphenidate, and different brands have different proportions of each. Brands may therefore vary in their release characteristics and clinical effect. Modified-released preparations should therefore be prescribed by brand name.  Methylphenidate is a schedule 2 controlled substance; all legal requirements for prescribing controlled drugs should be followed. See NICE Guidance NG46 Controlled drugs: safe use and management. Risk of misuse can be reduced by using modified-release preparations.  Where a person with ADHD is treated by a Child and Adolescent Mental Health Service (CAMHS) but is approaching their 18th birthday, it is expected that CAMHS will refer to the appropriate adult service if need for ongoing treatment is anticipated.  The safety and efficacy of long-term use of methylphenidate has not been systematically evaluated in controlled trials. Patients should be reviewed for ongoing need at least annually, and the manufacturers recommend a trial discontinuation at least once yearly to assess the patient’s condition.  Methylphenidate is not licensed for all the indications it is used to treat below. However, its use for the indications below are established and supported by various sources and bodies including the BNF and NICE. |

|  |  |  |
| --- | --- | --- |
| Indications [Back to top](#Responsibilities) | | |
| * Attention deficit hyperactivity disorder (ADHD) in adults * Narcolepsyǂ   ǂ Off-label indication. Please note licensed indications vary by manufacturer; see [SPC](https://www.medicines.org.uk/emc/search?q=methylphenidate) for full details. Some brands are not licensed in adults (see [section 6](#Six_pharmaceutical))  Off-Label use in the treatment of ADHD in adults is endorsed by NICE Clinical Guideline 87 | | |
| Locally agreed off-label use [Back to top](#Responsibilities) | | |
| The South West London Integrated Medicines Optimisation Committee recommended the use of this document for the indications as outlined above.  The following information should be provided in correspondence to support prescribing in line with this shared care.   * Dosing specific to the indication * Relevant interaction information * Any additional monitoring requirements over and above the shared care. * Duration of treatment * Frequency of review * Specific features of adverse effects or deterioration pertinent to the specific indication for which it is used | | |
| Contraindications and cautions [Back to top](#Responsibilities) This information does not replace the Summary of Product Characteristics (SPC), and should be read in conjunction with it. Please see [BNF](https://bnf.nice.org.uk/drugs/) & [SPC](https://www.medicines.org.uk/emc/) for comprehensive information. | | |
| Contraindications:Hypersensitivity to methylphenidate or to any of the excipientsGlaucomaPhaeochromocytomaDuring treatment with non-selective, irreversible monoamine oxidase (MAO) inhibitors, or within a minimum of 14 days of discontinuing those drugs, due to the risk of hypertensive crisisHyperthyroidism or thyrotoxicosisDiagnosis or history of severe depression, anorexia nervosa/anorexic disorders, suicidal tendencies, psychotic symptoms, severe mood disorders, mania, schizophrenia, psychopathic/borderline personality disorder.Diagnosis or history of severe and episodic (Type I) bipolar (affective) disorder (that is not well-controlled).Certain pre-existing cardiovascular disorders constitute contraindications unless specialist cardiac advice is obtained and documented. These include severe hypertension, heart failure, arterial occlusive disease, angina, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias, disorders caused by the dysfunction of ion channels, and structural cardiac abnormalities.Pre-existing cerebrovascular disorders cerebral aneurysm, vascular abnormalities including vasculitis or stroke.Medikinet XL only: history of pronounced anacidity of the stomach with a pH value above 5.5, or during therapy with H2 receptor blockers, proton pump inhibitors or antacids. **Cautions:**   * Family history of sudden cardiac or unexplained death, malignant arrhythmia. * Cardiovascular status should be carefully monitored (see [section 9](#Nine_primary_care_monitoring) & [section 10](#Ten_ADRs_and_Management)) * Underlying conditions which might be compromised by increases in blood pressure or heart rate. * Known drug or alcohol dependency or misuse of central nervous system (CNS) stimulants: potential for abuse, misuse or diversion. * Alcohol consumption (not recommended during treatment) * Epilepsy: may lower seizure threshold * Psychiatric and neuropsychiatric symptoms or disorders, including manic or psychotic symptoms, aggressive or hostile behaviour, motor or verbal tics (including Tourette’s syndrome), anxiety, agitation or tension, depressive symptoms, bipolar disorder. * Renal or hepatic insufficiency (due to lack of data) * Leukopenia, thrombocytopenia, anaemia, or other haematological abnormalities. * Prolonged-release tablets only: severe narrowing of the gastrointestinal tract or dysphagia; risk of obstruction * Safety and efficacy has not been established in patients older than 60 years of age. * Susceptibility to open-angle glaucoma. * Pregnancy or breast-feeding (see [section 12](#Twelve_pregnancy_paternity))  Potential for abuse, misuse, or diversion. | | |
| Initiation and ongoing dose regimen [Back to top](#Responsibilities)  * Transfer of monitoring and prescribing to primary care is normally after at least 12 weeks, and when the patient’s dose has been optimised and with satisfactory investigation results for at least 4 weeks. * The duration of treatment & frequency of review will be determined by the specialist, based on clinical response and tolerability. * All dose or formulation adjustments will be the responsibility of the initiating specialist unless directions have been discussed and agreed with the primary care clinician. * Termination of treatment will bethe responsibility of the specialist. | | |
| **Initial stabilisation:**  **Recommended starting dose in ADHD**:   * Immediate release tablets: 5 mg, given 2-3 times daily * Modified release tablets: 18 mg daily, given in the morning * Modified release capsules: 10-20 mg daily   Adults with ADHD who have shown clear benefit from methylphenidate in childhood or adolescence may continue treatment into adulthood at the same daily dose. [Consult SPC for the prescribed brand for more information.](https://www.medicines.org.uk/emc/search?q=methylphenidate)  **Recommended starting dose in narcolepsy (off-label)**:   * Immediate release tablets: 10 mg daily in divided doses, to be taken before meals   **During initiation Methylphenidate** **must be prescribed by the initiating specialist during initiation and dose stabilisation.**  **Maintenance dose (following initial stabilisation):**  The dose of methylphenidate should be titrated to response, usually at weekly intervals.  **Maximum dose in ADHD:**   * Immediate release tablets: up to 100 mg daily in 2-3 divided doses * Modified release tablets: up to 108 mg once daily, given in the morning * Modified release capsules: up to 100 mg daily. May be given as a single dose in the morning or in divided doses in the morning and at midday, depending on brand.   The maximum licensed daily dose varies with formulation and brand; consult [BNF](https://bnf.nice.org.uk/drug/methylphenidate-hydrochloride.html) and [SPC](https://www.medicines.org.uk/emc/search?q=methylphenidate).  **Usual dose in narcolepsy (off-label)**:   * Immediate release tablets: 20-30 mg daily in divided doses, taken before meals. Maximum dose 60 mg daily   **The initial maintenance dose must be prescribed by the initiating specialist.**  **Conditions requiring dose adjustment:**  Consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. This should be undertaken and supervised by the specialist who will advise the patient and primary care prescriber of the outcome. | | |
| Pharmaceutical aspects [Back to top](#Responsibilities) | | |
| Route of administration: | Oral | |
| Formulation: | Methylphenidate hydrochloride.  **Standard release tablets:**  Medikinet®: 5mg, 10mg, 20mg  Methylphenidate hydrochloride (generic): 5mg, 10mg, 20mg  Ritalin®: 10mg  Tranquilyn®: 5mg, 10mg, 20mg  **NB: Methylphenidate standard release tablets are not licensed for use in adults. Off-Label use in adults is endorsed by NICE Clinical Guideline 87..** Brand name prescribing is not necessary for standard release tablets.  **Prolonged-release tablets:**  NB: Modified-released preparations vary in their release characteristics and must be prescribed by brand name. The specialist must specify the brand to be prescribed.  Affenid® XL: 18mg, 27mg, 36mg, 54mg  Concerta XL®: 18mg, 27mg, 36mg, 54mg  Delmosart®: 18mg, 27mg, 36mg, 54mg  \*Matoride XL®: 18mg, 36mg, 54mg  Xaggitin XL®: 18mg, 27mg, 36mg, 54mg  Xenidate XL®: 18mg, 27mg, 36mg, 54mg  **NB: Affenid XL , Concerta XL, Delmosart XL, Xaggitin XL and Xenidate XL modified-release tablets are licensed for initiation and continuation in adults**  **\* Matoride XL tablets are not licensed for intiation in adults. Off-Label use in adults is endorsed by NICE Clinical Guideline 87.**  **Modified-release capsules:**  NB: Modified-released preparations vary in their release characteristics and must be prescribed by brand name. The specialist must specify the brand to be prescribed.  Equasym XL®: 10mg, 20mg, 30mg  Medikinet XL®▼: 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg  Meflynate XL®: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg  Metyrol XL®: 10mg, 20mg, 30mg, 40mg, 50mg, 60mg  Ritalin XL®: 10mg, 20mg, 30mg, 40mg, 60mg  **NB: Ritalin XL and Medikinet XL modified-release capsules are licensed for initiation and continuation in adults.**  **Equasym XL is not licensed for use in adults. Off-Label use in adults is endorsed by NICE Clinical Guideline 87.**  **Please consult the relevant** [**SPC**](https://www.medicines.org.uk/emc/search?q=methylphenidate) **for brand-specific licensing information.** | |
| Administration details: | Methylphenidate can be taken with or without food, but patients should standardise which method is chosen.  Administration requirements vary by formulation and brand. Methylphenidate capsules can be opened and sprinkled on a small amount of soft food for administration. Please consult the relevant [SPC](https://www.medicines.org.uk/emc/search?q=methylphenidate) for brand-specific information.  If a dose is missed then the next scheduled dose should be taken as usual; a double dose should not be taken to make up for a missed dose. | |
| Other important information: | Methylphenidate is a schedule 2 controlled drug and is subject to [legal prescription requirements](https://bnf.nice.org.uk/guidance/controlled-drugs-and-drug-dependence.html). It has the potential for misuse and diversion.  The choice of formulation will be decided by the treating specialist on an individual basis, and depends on the intended duration of effect. Risk of misuse can be reduced by using modified-release preparations.  Alcohol may exacerbate CNS adverse effects of methylphenidate and should be avoided during use.  Methylphenidate may cause false positive laboratory test results for amphetamines. | |
| Significant medicine interactions [Back to top](#Responsibilities) The following list is not exhaustive. Please see [BNF](https://bnf.nice.org.uk/drugs/) or [SPC](https://www.medicines.org.uk/emc/) for comprehensive information and recommended management. | | |
| * **Monoamine oxidase inhibitors (MAOIs):** risk of hypertensive crisis. The combination should be avoided, and use of methylphenidate and MAOIs should be separated by at least 14 days * **Coumarin anticoagulants, anticonvulsants (e.g. phenobarbital, phenytoin, primidone), selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants**:metabolism may be inhibited by methylphenidate.Dose adjustment may be required when starting or stopping methylphenidate. * **Anti-hypertensive drugs**: effectiveness may be reduced by methylphenidate * **Other drugs which elevate blood pressure:** risk of additive effects (e.g. linezolid) * **Alcohol:** may exacerbate adverse CNS effects of methylphenidate * **Serotonergic drugs**, including SSRIs and MAOIs**:** increased risk of central nervous system (CNS) adverse effects, risk of serotonin syndrome * **Halogenated anaesthetics:** risk of sudden blood pressure increase during surgery. Avoid methylphenidate on the day of planned surgery. * **Dopaminergic drugs**, **including antipsychotics**: increased risk of pharmacodynamic interactions including dyskinesias or hypertensive crisis (e.g. risperidone, paliperidone, selegiline, rasagiline) * **Apraclonidine:** effects decreased by methylphenidate. * **Carbamazepine:** may decrease methylphenidate levels * **Ozanimod:** may increase risk of hypertensive crisis | | |
| Baseline investigations, initial monitoring and ongoing monitoring to be undertaken by specialist [Back to top](#Responsibilities) Monitoring at baseline and during initiation is the responsibility of the specialist; only once the patient is optimised on the chosen medication with no anticipated further changes expected in immediate future will prescribing and monitoring be transferred to primary care. | | |
| **Baseline investigations:**   * A medical history and cardiovascular assessment, taking into account conditions that may be contraindications, risk of pregnancy (where applicable), and to ensure the patient meets the criteria for ADHD and that pharmacological treatment is required * Risk assessment for substance misuse and drug diversion * Height, weight, and body mass index (BMI) * Blood pressure (BP) and heart rate * Arrange for electrocardiogram (ECG), only if the patient has any of the following:   + History of congenital heart disease or previous cardiac surgery   + Sudden death in a first-degree relative under 40 years suggesting a cardiac disease   + Shortness of breath on exertion compared with peers   + Fainting on exertion or in response to fright or noise   + Palpitations   + Chest pain suggestive of cardiac origin   + Signs of heart failure, heart murmur or hypertension   + Current treatment with a medicine that may increase cardiac risk   **Initial monitoring:**   * Before every change of dose: assess heart rate, blood pressure, and weight. * After every change of dose: assess heart rate and blood pressure, and any new or worsening psychiatric symptoms. The specialist should determine the appropriate timing for this monitoring. * Assessment of symptom improvement. Discontinue if no improvement is observed after one month.   **Ongoing monitoring (ADHD):**  Ensure the patient receives a review at least annually with a healthcare professional with training and expertise in managing ADHD. This may be in primary or secondary care, depending on local arrangements, and should include a review of ADHD medication, including patient preferences, benefits, adverse effects, and ongoing clinical need. Consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. If continuing medication, document the reasons why.  Review outcomes should be communicated to the primary care prescriber in writing, with any urgent changes also communicated by telephone. | | |
| Ongoing monitoring requirements to be undertaken  by primary care [Back to top](#Responsibilities) See [section 10](#Ten_ADRs_and_Management) for further guidance on management of adverse effects/responding to monitoring results. | | |
| **Monitoring** | | **Frequency** |
| * Blood pressure and heart rate, and assessment for cardiovascular signs or symptoms * Weight and appetite * Assessment for new or worsening psychiatric and neurological signs or symptoms (e.g. tics, anxiety, symptoms of bipolar disorder) * Explore whether patient is experiencing any difficulties with sleep | | Every 6 months, and after any change of dose recommended by specialist team. |
| * Assessment of adherence, and for any indication of methylphenidate abuse, misuse, or diversion | | As required, based on the patient’s needs and individual circumstances |
| * Review to ensure patient has been offered and attended an annual review with a healthcare professional with expertise in ADHD | | Annually |
| **(If relevant) If monitoring results are forwarded to the specialist team, please include clear clinical information on the reason for sending, to inform action to be taken by secondary care.** | | |
| Adverse effects and other management [Back to top](#Responsibilities) **Any serious adverse reactions should be reported to the MHRA via the Yellow Card scheme. Visit** [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)  For information on incidence of ADRs see relevant summaries of product characteristics | | |
| **Result** | | **Action for primary care** |
| **As well as responding to absolute values in laboratory tests, a rapid change or a consistent trend in any value should prompt caution and extra vigilance.** | | |
| **Cardiovascular**  Resting HR greater than 120bpm, arrhythmia/palpitations, clinically significant increase in systolic BP | | * In context of recent dose increase, revert to previous dose and discuss with specialist for ongoing management * In absence of recent dose changes, reduce dose by half and discuss with specialist or cardiology for further advice. |
| **Weight or BMI outside healthy range**, anorexia or weight loss | | Exclude other reasons for weight loss. Give advice as per [NICE NG87](https://www.nice.org.uk/guidance/ng87/):   * take medication with or after food, not before * additional meals or snacks early in the morning or late in the evening when stimulant effects have worn off * obtaining dietary advice * consuming high-calorie foods of good nutritional value   Discuss with specialist if difficulty persists; dose reduction, treatment break, or change of medication may be required. |
| **Haematological disorders**  Including leukopenia, thrombocytopenia, anaemia or other alterations  NB: no haematological monitoring is recommended. Haematological disorders would be a chance finding/due to patient reporting adverse drug reactions. | | Contact specialist team. Discontinuation should be considered. Referral to haematology may be warranted; use clinical discretion. |
| **Psychiatric disorders**  New or worsening psychiatric symptoms, e.g. psychosis, mania, aggressive or hostile behaviour, suicidal ideation or behaviour, motor or verbal tics (including Tourette’s syndrome), anxiety, agitation or tension, bipolar disorder, depression | | Discuss with specialist. Stop treatment and consider referral to acute mental health team if suicidal thoughts, mania, or psychosis are present Methylphenidate should not be continued unless the benefits outweigh the risks. |
| **Nervous system disorders**  Symptoms of cerebral ischaemia, e.g. severe headache, numbness, weakness, paralysis, and impairment of coordination, vision, speech, language or memory | | Discontinue methylphenidate, refer urgently for neurological assessment |
| New or worsening seizures | | Discontinue methylphenidate. Discuss with specialist team. |
| Symptoms of serotonin syndrome, e.g. agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, rigidity, nausea, vomiting, diarrhoea | | Discontinue methylphenidate as soon as possible. Management depends on severity; use clinical judgement and seek advice if necessary.  Discuss with specialist team to determine whether methylphenidate can be re-started. |
| Insomnia or other sleep disturbance | | Review timing of methylphenidate dose and advise as appropriate. Give advice on sleep hygiene.  Discuss with specialist if difficulty persists; dose reduction may be required. |
| Suspicion of abuse, misuse, or diversion | | Discuss with specialist team |
| Advice to patients and carers [Back to top](#Responsibilities) The specialist will counsel the patient with regard to the benefits and risks of treatment and will provide the patient with any relevant information and advice, including patient information leaflets on individual medicines. | | |
| **The patient should be advised to report any of the following signs or symptoms to their primary care prescriber without delay:**   * Abnormally sustained or frequent and painful erections: seek immediate medical attention. * Signs or symptoms of serotonin syndrome (e.g. agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, hyperreflexia, incoordination, rigidity, nausea, vomiting, diarrhoea) * Any mood changes, for example. psychosis, mania, aggressive or hostile behaviour, suicidal ideation or behaviour, motor or verbal tics (including Tourette’s syndrome), anxiety, agitation or tension, anxiety, depression * New or worsening neurological symptoms (e.g. severe headache, numbness, weakness, paralysis, and impairment of coordination, vision, speech, language or memory) * Abdominal pain, malaise, jaundice or darkening of urine * Skin rashes, or bruising easily * If they suspect they may be pregnant, or are planning a pregnancy. Patients of childbearing potential should use appropriate contraception, and take a pregnancy test if they think there is a possibility they could be pregnant.   **The patient should be advised:**   * Attend regularly for monitoring and review appointments with primary care and specialist, and keep contact details up to date with both prescribers. It may not be safe to continue prescribing without regular review, and patients should be aware that their medicines could be stopped if they do not attend appointments. * Not to drive or operate machines if methylphenidate affects their ability to do so safely, e.g. by causing dizziness, drowsiness, or visual disturbances. * People who drive must inform the DVLA if their ADHD, narcolepsy or medicines affect their ability to drive safely. See <https://www.gov.uk/adhd-and-driving> or <https://www.gov.uk/narcolepsy-and-driving>. * Avoid alcohol while taking methylphenidate, as it may make side effects worse. Avoid recreational drugs. * Not to stop taking methylphenidate without talking to their doctor. Medical supervision of withdrawal is required, since this may unmask depression or chronic over-activity. * Methylphenidate is a schedule 2 controlled drug. Patients may be required to prove their identity when collecting prescriptions, and should store methylphenidate safely and securely. It must not be shared with anyone else. There are restrictions on travelling with controlled drugs: see <https://www.gov.uk/guidance/controlled-drugs-personal-licences>.   Patient information:   * Royal College of Psychiatrists – ADHD in adults. <https://www.rcpsych.ac.uk/mental-health/problems-disorders/adhd-in-adults> * NHS – Attention deficit hyperactivity disorder. <https://www.nhs.uk/conditions/attention-deficit-hyperactivity-disorder-adhd/> * Narcolepsy UK – methylphenidate. <https://www.narcolepsy.org.uk/resources/methylphenidate>   NHS – Narcolepsy. <https://www.nhs.uk/conditions/narcolepsy/> | | |
| Pregnancy, paternal exposure and breast feeding [Back to top](#Responsibilities) It is the responsibility of the specialist to provide advice on the need for contraception to male and female patients on initiation and at each review, but the ongoing responsibility for providing this advice rests with both the primary care prescriber and the specialist. | | |
| **Pregnancy:**  Methylphenidate is not recommended for use during pregnancy unless a clinical decision is made that postponing treatment may pose a greater risk to the pregnancy.  Evidence on exposure to methylphenidate during pregnancy is too limited to draw firm conclusions on adverse outcomes. Clinicians should be aware that patients may have other risk factors which independently alter the risks.  Patients who become pregnant while taking methylphenidate, or who plan a pregnancy, should be referred to the specialist team for review. The specialist will reassume prescribing responsibility, ending the shared care agreement.  Healthcare professional information available from: <https://www.medicinesinpregnancy.org/bumps/monographs/USE-OF-METHYLPHENIDATE-IN-PREGNANCY/> Updated 09/11/2023: [USE OF METHYLPHENIDATE IN PREGNANCY – UKTIS](https://uktis.org/monographs/use-of-methylphenidate-in-pregnancy/)  Patient information available from: <https://www.medicinesinpregnancy.org/Medicine--pregnancy/Methylphenidate/>  **Breastfeeding:**  Methylphenidate has been found in breast milk in small amounts. Evidence for safety in breastfeeding is limited. Decisions to use while breastfeeding should be made on a case-by-case basis, taking into account the risks to the infant and benefits of therapy. Infants should be monitored for symptoms of CNS stimulation (e.g. decreased appetite/weight gain, sleep disturbances, irritability), although these may be difficult to detect. High doses may interfere with lactation, although this is not confirmed in practice.  Healthcare professional information available from: <https://www.sps.nhs.uk/articles/safety-in-lactation-drugs-for-adhd/>  **Paternal exposure:**  No evidence regarding adverse outcomes following paternal exposure was identified.  Further information for patients: [bumps - best use of medicine in pregnancy (medicinesinpregnancy.org)](https://www.medicinesinpregnancy.org/Medicine--pregnancy/Methylphenidate/) | | |

|  |
| --- |
| Specialist contact information [Back to top](#Responsibilities) |
| Name: *[See coversheet]*  Role and specialty: *[See coversheet]*  Daytime telephone number: *[See coversheet]*  Email address: *[See coversheet]*  Alternative contact: *[See coversheet]*  Out of hours contact details: *[*If a patient is in crisis, please contact the Mental Health Support Line on 0800 028 8000- Calls are accepted 24 hours a day 7 days a week. It will act as the central point of crisis contact at the Trust.  If a patient requires urgent psychiatric treatment, they should call 999 or attend A&E.*]* |
| Additional information [Back to top](#Responsibilities) |
| Where patient care is transferred from one specialist service or GP practice to another, a new shared care agreement must be completed. Ensure that the specialist is informed in writing of any changes to the patient’s GP or their contact details. |
| References [Back to top](#Responsibilities) |
| * eBNF. Methylphenidate. Accessed via <https://bnf.nice.org.uk/> on 14/04/2021 * Methylphenidate hydrochloride 5 mg tablets (Medikinet®). Date of revision of the text 29/01/2021. Accessed via <https://www.medicines.org.uk/emc/product/328/smpc> * Methylphenidate hydrochloride 10 mg tablets (Ritalin®). Date of revision of the text 10/12/20. Accessed via <https://www.medicines.org.uk/emc/product/1035/smpc> Update 09/11/23 Accessed via <https://mhraproducts4853.blob.core.windows.net/docs/3964ad158b3f04104052695e8693f8797eb48589> * Methylphenidate hydrochloride 5 mg tablets (Tranquilyn®). Date of revision of the text 21/09/20. Accessed via <https://products.mhra.gov.uk/> * Methylphenidate hydrochloride 5 mg tablets (Mylan). Date of revision of the text October 2019. Accessed via <https://www.medicines.org.uk/emc/product/8724/smpc> * Methylphenidate hydrochloride 18 mg prolonged-release tablets (Concerta XL®). Date of revision of the text 07/10/20. Accessed via <https://www.medicines.org.uk/emc/product/6872/smpc> * Methylphenidate hydrochloride 18 mg prolonged-release tablets (Delmosart®). Date of revision of the text 21/09/20. Accessed via <https://www.medicines.org.uk/emc/product/2337/smpc.> Updated 09/11/23 via <https://mhraproducts4853.blob.core.windows.net/docs/034cdf7d932a39d527a9a0b02b63035369a62c0c> * Methylphenidate hydrochloride 18 mg prolonged-release tablets (Matoride XL®). Date of revision of the text 05/11/2020. Accessed via <https://www.medicines.org.uk/emc/product/3682/smpc> * Methylphenidate hydrochloride 18 mg prolonged-release tablets (Xaggitin XL®). Date of revision of the text December 2020. Accessed via <https://www.medicines.org.uk/emc/product/2704/smpc> * Methylphenidate hydrochloride 18 mg prolonged-release tablets (Xenidate XL®). Date of revision of the text 05/02/2021. Accessed via <https://www.medicines.org.uk/emc/product/4397/smpc> * Methylphenidate hydrochloride 10 mg prolonged-release capsules (Equasym XL®). Date of revision of the text 16/12/2020. Accessed via <https://www.medicines.org.uk/emc/product/3887/smpc> * Methylphenidate hydrochloride 10 mg prolonged-release capsules (Medikinet XL®▼). Date of revision of the text 29/01/2021. Accessed via <https://www.medicines.org.uk/emc/product/313/smpc> * Methylphenidate hydrochloride 10 mg prolonged-release capsules (Ritalin XL®). Date of revision of the text 03/11/20. Accessed via <https://www.medicines.org.uk/emc/product/11094/smpc.> Updated 09/11/23 via <https://mhraproducts4853.blob.core.windows.net/docs/2148163b330b83446eccd2c0d8cebe06411297e5> * NICE NG87: Attention deficit hyperactivity disorder: diagnosis and management. Last updated September 2019. Accessed via <https://www.nice.org.uk/guidance/ng87/> on 14/04/21 * NICE Clinical Knowledge Summaries. Attention deficit hyperactivity disorder: Methylphenidate. Last revised January 2021. Accessed via <https://cks.nice.org.uk/topics/attention-deficit-hyperactivity-disorder/prescribing-information/methylphenidate/> on 04/05/2021 * Specialist Pharmacy Service. Medicines Q&A: Which medicines should be considered for brand-name prescribing in primary care? [Prescribing by generic or brand name in primary care – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice](https://www.sps.nhs.uk/articles/prescribing-by-generic-or-brand-name-in-primary-care/#:~:text=brand%20name) on 05/05/2021 * Home Office. Guidance: List of most commonly encountered drugs currently controlled under the misuse of drugs legislation. Updated December 2019. Accessed via <https://www.gov.uk/government/publications/controlled-drugs-list--2/list-of-most-commonly-encountered-drugs-currently-controlled-under-the-misuse-of-drugs-legislation> on 05/05/2021 * NICE. NG46: Controlled drugs: safe use and management. April 2016. Accessed via <https://www.nice.org.uk/guidance/ng46/> on 05/05/2021 * Methylphenidate (MPH): physician’s guide to prescribing. Accessed via <http://www.methylphenidate-guide.eu/gb/welcome.php> on 14/04/21 * Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology. Bolea-Alamañac B, Nutt DJ, Adamou M, et al. Journal of Psychopharmacology. 2014. 1–25. DOI: [10.1177/0269881113519509](https://doi.org/10.1177/0269881113519509) * UKTIS. Use of methylphenidate in pregnancy. Last updated January 2018. Accessed via <https://www.toxbase.org/poisons-index-a-z/m-products/methylphenidate-in-pregnancy/> on 14/04/2021 * Specialist Pharmacy Service. Safety in Lactation: Drugs for ADHD. Last updated October 2020. Accessed via <https://www.sps.nhs.uk/articles/safety-in-lactation-drugs-for-adhd/> on 05/05/2021 * Specialist Pharmacy Service. Methylphenidate Lactation Safety Information. Last updated September 2018. Accessed via <https://www.sps.nhs.uk/medicines/methylphenidate/> on 05/05/2021 |
| Other relevant national guidance [Back to top](#Responsibilities) |
| * Shared Care for Medicines Guidance – A Standard Approach (RMOC). Available from <https://www.sps.nhs.uk/articles/rmoc-shared-care-guidance/> * NHSE guidance – Responsibility for prescribing between primary & secondary/tertiary care. Available from <https://www.england.nhs.uk/publication/responsibility-for-prescribing-between-primary-and-secondary-tertiary-care/> * General Medical Council. Good practice in prescribing and managing medicines and devices. Shared care. Available from <https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices/shared-care> * NICE NG197: Shared decision making. Last updated June 2021. <https://www.nice.org.uk/guidance/ng197/>. |
| Local arrangements for referral [Back to top](#Responsibilities) Define the referral procedure from hospital to primary care prescriber & route of return should the patient’s condition change. |
| Follow Place based processes |

# Appendix 1: Shared Care Request letter (Specialist to Primary Care Prescriber)

Dear: *[insert Primary Care Prescriber's name]*

Patient name: *[insert Patient's name]*

Date of birth: *[insert patient's date of birth]*

NHS Number*: [insert NHS Number]*

Diagnosis: *[insert diagnosis]*

As per the agreed SWL shared care protocol for *[insert medicine name]* for the treatment of [*insert indication*]*,* this patient is now suitable for prescribing to move to primary care.

The patient fulfils criteria for shared care, and I am therefore requesting your agreement to participate in shared care. Where baseline investigations are set out in the shared care protocol, I have carried these out.

I can confirm that the following has happened with regard to this treatment:

|  |  |
| --- | --- |
|  | **Specialist to complete** |
| *The patient has been initiated on this therapy and has been on an optimised dose for the following period of time:* |  |
| *Baseline investigation and monitoring as set out in the shared care documents have been completed and were satisfactory* | *Please add dates.*  ***Baseline BP:……***  ***Current BP:……..***  ***Baseline heartrate:………***  ***Current heart rate:………..***  ***Baseline weight:…………***  ***Current weight:………*** |
| *The condition being treated has a predictable course of progression and the patient can be suitably maintained by primary care* | *Yes / No* |
| *The risks and benefits of treatment have been explained to the patient* | *Yes / No* |
| *The roles of the specialist/specialist team/* *Primary Care Prescriber / Patient and pharmacist have been explained and agreed* | *Yes / No* |
| *The patient has agreed to this shared care arrangement, understands the need for ongoing monitoring, and has agreed to attend all necessary appointments* | *Yes / No* |
| *I have enclosed a copy of the shared care protocol which covers this treatment/the SCP can be found here:* [*Shared Care Agreements – SW London Integrated Medicines Optimisation Committee (icb.nhs.uk)*](https://swlimo.southwestlondon.icb.nhs.uk/policies/shared-care-prescribing-guidelines-and-transfer-of-care-agreements/shared-care-agreements/) | *Yes / No* |
| *I have included with the letter copies of the information the patient has received* | *Yes / No* |
| *I have provided the patient with sufficient medication to last until* |  |
| *I have arranged a follow up with this patient in the following timescale* |  |

**Annual review to be completed by**:

|  |  |
| --- | --- |
| Specialist | Yes / No |
| Primary care clinician  *Only where local arrangements allow for this and if the primary care clinician is happy to do this* | Yes / No |

Treatment was started on *[insert date started]* and the current dose is *[insert dose and frequency]*.

If you are in agreement, please undertake monitoring and treatment from *[insert date]* NB: date must be at least 1 month from initiation of treatment.

The next blood monitoring is due on *[insert date]* and should be continued in line with the shared care guideline.

Please respond to this request for shared care, in writing, within 14 days of the request being made where possible.

# Appendix 2: Shared Care Agreement Letter (Primary Care Prescriber to Specialist)

**Primary Care Prescriber Response**

Dear *[insert Doctor's name]*

Patient *[insert Patient's name]*

NHS Number *[insert NHS Number]*

Identifier *[insert patient's date of birth and/or address]*

Thank you for your request for me to accept prescribing responsibility for this patient under a shared care agreement and to provide the following treatment

|  |  |  |
| --- | --- | --- |
| Medicine | Route | Dose & frequency |
|  |  |  |

**Annual review to be completed by**:

|  |  |
| --- | --- |
| Specialist | Yes / No |
| Primary care clinician  *Only where local arrangements allow for this and if the primary care clinician is happy to do this* | Yes / No |

I can confirm that I am willing to take on this responsibility from *[insert date]* and will complete the monitoring as set out in the shared care protocol for this medicine/condition.

Primary Care Prescriber signature:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Date: \_\_\_\_\_\_\_\_\_\_\_\_

Primary Care Prescriber address/practice stamp

# Appendix 3: Shared Care Refusal Letter (Primary Care Prescriber to Specialist)

**Re:**

Patient *[insert Patient's name]*

NHS Number *[insert NHS Number]*

Identifier *[insert patient's date of birth and/or address]*

Thank you for your request for me to accept prescribing responsibility for this patient.

In the interest of patient safety NHS SWL ICB**,** in conjunction with local acute trusts have classified *[insert medicine name]* as a Shared Care drug, and requires a number of conditions to be met before transfer can be made to primary care.

**I regret to inform you that in this instance I am unable to take on responsibility due to the following:**

|  |  |  |
| --- | --- | --- |
|  |  | **Tick which apply** |
| **1.** | **The prescriber does not feel clinically confident in managing this individual patient’s condition, and there is a sound clinical basis for refusing to accept shared care**  As the patients primary care prescriber I do not feel clinically confident to manage this patient’s condition because *[insert reason].* I have consulted with other primary care prescribers in my practice who support my decision. This is not an issue which would be resolved through adequate and appropriate training of prescribers within my practice.  **I have discussed my decision with the patient and request that prescribing for this individual remain with you as the specialist, due to the sound clinical basis given above.** |  |
| **2.** | **The medicine or condition does not fall within the criteria defining suitability for inclusion in a shared care arrangement**  As the medicine requested to be prescribed is not included on the national list of shared care drugs as identified by RMOC or is not a locally agreed shared care medicine I am unable to accept clinical responsibility for prescribing this medication at this time.  **Until this medicine is identified either nationally or locally as requiring shared care the responsibility for providing this patient with their medication remains with you** |  |
| **3.** | **A minimum duration of supply by the initiating clinician**  As the patient has not had the minimum supply of medication to be provided by the initiating specialist I am unable to take clinical responsibility for prescribing this medication at this time. Therefore can you please contact the patient as soon as possible in order to provide them with the medication that you have recommended.  ***Until the patient has had the appropriate length of supply the responsibility for providing the patient with their medication remains with you.*** |  |
| **4.** | **Initiation and optimisation by the initiating specialist**  As the patient has not been optimised on this medication I am unable to take clinical responsibility for prescribing this medication at this time. Therefore can you please contact the patient as soon as possible in order to provide them with the medication that you have recommended.  ***Until the patient is optimised on this medication the responsibility for providing the patient with their medication remains with you.*** |  |
| **5.** | **Shared Care Protocol not received**  As legal responsibility for clinical care lies with the clinician who signs the prescription, I need to ensure that I am in possession of sufficient clinical information for me to be confident to prescribe this treatment for my patient and it is clear where each of our responsibilities lie to ensure the patient is safely managed***.***  For this reason I am unable to take clinical responsibility for prescribing this medication at this time, therefore would you please contact the patient as soon as possible in order to provide them with the medication that you have recommended.  ***Until I receive the appropriate SCP, responsibility for providing the patient with their medication remains with you.*** |  |
| **6.** | **Other (Primary Care Prescriber to complete if there are other reasons why shared care cannot be accepted)** |  |

I would be willing to consider prescribing for this patient once the above criteria have been met for this treatment.

NHS England ‘Responsibility for prescribing between Primary & Secondary/Tertiary care’ guidance (2018) states that “when decisions are made to transfer clinical and prescribing responsibility for a patient between care settings, it is of the utmost importance that the GP feels clinically competent to prescribe the necessary medicines. It is therefore essential that a transfer involving medicines with which GPs would not normally be familiar should not take place without full local agreement, and the dissemination of sufficient, up-to-date information to individual GPs.” In this case we would also see the term GP being interchangeable with the term Primary Care Prescriber.

Please do not hesitate to contact me if you wish to discuss any aspect of my letter in more detail and I hope to receive more information regarding this shared care agreement as soon as possible

Yours sincerely

**Primary Care Prescriber signature: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Date: \_\_\_\_\_\_\_\_\_\_\_\_**

**Primary Care Prescriber address/practice stamp**